WT1 contributes to leukemogenesis: expression patterns in 7,12-dimethylbenz[a]anthracene (DMBA)-induced leukemia

Area of Science:

• Oncology
• Molecular Biology
• Hematology

Background:

• The Wilms' tumor gene (WT1) is typically considered a tumor suppressor.
• Its role in certain leukemias, particularly during leukemogenesis, remains unclear.
• The 7,12-dimethylbenz[a]anthracene (DMBA)-induced rat leukemia model offers a system to study these processes.

Purpose of the Study:

• To investigate the involvement of WT1 expression during DMBA-induced leukemogenesis in rats.
• To determine if WT1 expression correlates with the development and progression of leukemia.

Main Methods:

• Utilized a DMBA-induced rat leukemia model.
• Employed semi-quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) to detect WT1 expression.
• Analyzed WT1 expression in normal, pre-leukemic, and leukemic rat cells.

Main Results:

• WT1 expression was detected in 71% (15/21) of DMBA-induced erythroblastic leukemias.
• WT1 expression was largely absent in normal and early pre-leukemic rats.
• A single case of WT1 expression was found in late pre-leukemic stages (1/8).
• GATA-1, an erythroid transcription factor, was co-expressed in 13 of 15 WT1-expressing leukemias (p < 0.05).

Conclusions:

• High WT1 expression levels are associated with the tendency for cells to develop into leukemia.
• WT1 appears to contribute to leukemogenesis in the later stages.
• WT1 expression is crucial for the proliferation and survival of certain leukemia cells.